<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00921362</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-NRO-SER-2006/2</org_study_id>
    <secondary_id>SER-01-S-06</secondary_id>
    <nct_id>NCT00921362</nct_id>
  </id_info>
  <brief_title>Seroquel (Quetiapine Fumarate) InPractice Evaluation Programme</brief_title>
  <official_title>Seroquel (Quetiapine Fumarate) InPractice Evaluation Programme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients eligible for entry into the study have a diagnosis of schizophrenia defined by
      Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria and of
      a chronic or sub-chronic nature.The primary purpose of the study is to observe symptoms
      changes over 6 months in schizophrenia in patients treated with Seroquel; additionally
      disease severity and treatment compliance are followed
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Brief Psychiatric Rating Scale - BPRS</measure>
    <time_frame>Monthly at every clinic visit- 7 times</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Severity of Illness</measure>
    <time_frame>Monthly/ at every clinic visit-7 times</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-S Clinical Global Impression Improvement CGI -I</measure>
    <time_frame>Monthly/ at every clinic visit except first visit- 6 times</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1387</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Schizophrenia patients under Seroquel treatment</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients eligible for entry into the study will have a diagnosis of schizophrenia defined
        by Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria
        and of a chronic or sub-chronic nature
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To assess at baseline and after treatment administration the severity of the illness
             in patients with schizophrenia, using the scores obtained after the application of the
             CGI scale

          -  To assess the changes in symptoms of patients treated with Seroquel for 24 weeks,
             using BPRS (Brief Psychiatry Rating Scale) as measuring tool

        Exclusion Criteria:

          -  All the patients who have a known hypersensitivity to Seroquel /quetiapine or any of
             its excipients will not be included in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>stina Pentiuc, Med Director</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Romania</affiliation>
  </overall_official>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2009</study_first_submitted>
  <study_first_submitted_qc>June 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2009</study_first_posted>
  <last_update_submitted>June 15, 2009</last_update_submitted>
  <last_update_submitted_qc>June 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2009</last_update_posted>
  <keyword>Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

